Cited by 662Alzheimer's disease research and treatmentsDrug Transport and Resistance MechanismsBarrier Structure and Function Studies

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

P-glycoprotein deficiency at the blood-brain barrier increases amyloid- deposition in an Alzheimer disease mouse model

Open access

Cirrito, J. R.·2005·Journal of Clinical Investigation

DOI 10.1172/jci25247PMC PMC1257538

Open this paper in CoChat — free account Open PDF

Abstract

Accumulation of amyloid-beta (Abeta) within extracellular spaces of the brain is a hallmark of Alzheimer disease (AD). In sporadic, late-onset AD, there is little evidence for increased Abeta production, suggesting that decreased elimination from the brain may contribute to elevated levels of Abeta and plaque formation. Efflux transport of Abeta across the blood-brain barrier (BBB) contributes to Abeta removal from the brain. P-glycoprotein (Pgp) is highly expressed on the luminal surface of brain capillary endothelial cells and contributes to the BBB. In Pgp-null mice, we show that [I]Abeta40 and [I]Abeta42 microinjected into the CNS clear at half the rate that they do in WT mice. When amyloid precursor protein-transgenic (APP-transgenic) mice were administered a Pgp inhibitor, Abeta levels within the brain interstitial fluid significantly increased within hours of treatment. Furthermore, APP-transgenic, Pgp-null mice had increased levels of brain Abeta and enhanced Abeta deposition compared with APP-transgenic, Pgp WT mice. These data establish a direct link between Pgp and Abeta metabolism in vivo and suggest that Pgp activity at the BBB could affect risk for developing AD as well as provide a novel diagnostic and therapeutic target.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci25247

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,366
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
Schinkel, A. H., Smit, J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Riele, H. T., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,284
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I. H., & Gottesman, M. M. (1999) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,526
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 907
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830

Show all 34 references

Sorted by citations

Items 201–300 of 662

In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain
Modarres, H. P., Janmaleki, M., Novin, M., Saliba, J., Moussa, F. E. H., Charan, M. R., Seyfoori, A., SadAbadi, H., Vandal, M., Nguyen, M. D., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.024 · Cited by 77
The microcirculation, the blood-brain barrier, and the neurovascular unit in health and Alzheimer disease: The aberrant pericyte is a central player
Divecha, Y. A., Rampes, S., Tromp, S., Boyanova, S., Fleckney, A. L., Fidanboylu, M., & Thomas, S. A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100052 · Cited by 83
The Interplay of ABC Transporters in Aβ Translocation and Cholesterol Metabolism: Implicating Their Roles in Alzheimer’s Disease
Behl, T., Kaur, I., Sehgal, A., Kumar, A., Uddin, M. S., & BUNGAU, S. G. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02211-x · Cited by 78
Modulation of the Blood–Brain Barrier for Drug Delivery to Brain
Han, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122024 · Cited by 78
Beta‐Amyloid Downregulates MDR1‐P‐Glycoprotein (Abcb1) Expression at the Blood‐Brain Barrier in Mice
Brenn, A., Grube, M., Peters, M., Fischer, A., Jedlitschky, G., Kroemer, H. K., Warzok, R., & Vogelgesang, S. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/690121 · Cited by 80
Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation
ElAli, A., Thériault, P., Préfontaine, P., & Rivest, S. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-75 · Cited by 72
Functional Expression of P-glycoprotein and Organic Anion Transporting Polypeptides at the Blood-Brain Barrier: Understanding Transport Mechanisms for Improved CNS Drug Delivery?
Abdullahi, W., Davis, T., & Ronaldson, P. (2017) · AAPS Journal · doi:10.1208/s12248-017-0081-9 · Cited by 67
SARS-CoV-2: is there neuroinvasion?
McQuaid, C., Brady, M., & Deane, R. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00267-y · Cited by 72
Preclinical Prediction of Human Brain Target Site Concentrations: Considerations in Extrapolating to the Clinical Setting
Westerhout, J., Danhof, M., & de Lange, E. C. M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22604 · Cited by 72
BACE-1 is expressed in the blood–brain barrier endothelium and is upregulated in a murine model of Alzheimer’s disease
Devraj, K., Poznanovic, S., Spahn, C., Schwall, G., Harter, P. N., Mittelbronn, M., Antoniello, K., Paganetti, P., Muhs, A., Heilemann, M., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15606463 · Cited by 63
ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders
Dutheil, F., Jacob, A., Dauchy, S., Beaune, P. H., Scherrmann, J., Declèves, X., & Loriot, M. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.510832 · Cited by 79
P‐glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer’s Disease
Sita, G., Hrelia, P., Tarozzi, A., & Morroni, F. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7905486 · Cited by 73
The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model
Katt, M. E., Mayo, L. N., Ellis, S., Mahairaki, V., Rothstein, J. D., Cheng, L., & Searson, P. C. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0139-4 · Cited by 69
Tryps and trips: cell trafficking across the 100-year-old blood–brain barrier
Bentivoglio, M., & Kristensson, K. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.03.007 · Cited by 78
Dysregulated Wnt Signalling in the Alzheimer’s Brain
Aghaizu, N. D., Jin, H., & Whiting, P. J. (2020) · Brain Sciences · doi:10.3390/brainsci10120902 · Cited by 70
Regulation of ABC Transporters at the Blood-Brain Barrier: New Targets for CNS Therapy
Hartz, A. M. S., & Bauer, B. (2010) · Molecular Interventions · doi:10.1124/mi.10.5.6 · Cited by 70
Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease
Abuznait, A. H., Cain, C. M., Ingram, D., Burk, D. H., & Kaddoumi, A. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01309.x · Cited by 69
Targeting regulation of ABC efflux transporters in brain diseases: A novel therapeutic approach
Potschka, H. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.004 · Cited by 71
In Vivo Labeling of Brain Capillary Endothelial Cells after Intravenous Injection of Monoclonal Antibodies Targeting the Transferrin Receptor
Paris‐Robidas, S., Émond, V., Tremblay, C., Soulet, D., & Calon, F. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071027 · Cited by 70
Addressing Blood–Brain Barrier Impairment in Alzheimer’s Disease
Sharma, C., Woo, H., & Kim, S. R. (2022) · Biomedicines · doi:10.3390/biomedicines10040742 · Cited by 72
Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 70
Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells.
Kania, K., Wijesuriya, H. C., Hladky, S., & Barrand, M. (2011) · Brain Research · doi:10.1016/j.brainres.2011.08.044 · Cited by 63
Alzheimer's disease and blood–brain barrier function—Why have anti-β-amyloid therapies failed to prevent dementia progression?
Pahnke, J., Walker, L. C., Scheffler, K., & Krohn, M. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.05.006 · Cited by 68
Regional P-Glycoprotein Activity and Inhibition at the Human Blood–Brain Barrier as Imaged by Positron Emission Tomography
Eyal, S., Ke, B., Muzi, M., Link, J. M., Mankoff, D. A., Collier, A. C., & Unadkat, J. D. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.11 · Cited by 67
P-glycoprotein regulates blood–testis barrier dynamics via its effects on the occludin/zonula occludens 1 (ZO-1) protein complex mediated by focal adhesion kinase (FAK)
Su, L., Mruk, D. D., Lui, W., Lee, W. M., & Cheng, C. Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111414108 · Cited by 65
P-glycoprotein Trafficking as a Therapeutic Target to Optimize CNS Drug Delivery
Davis, T. P., Sanchez‐Covarrubias, L., & Tome, M. E. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.06.009 · Cited by 66
Ketone Bodies Promote Amyloid-β1–40 Clearance in a Human in Vitro Blood–Brain Barrier Model
Versele, R., Corsi, M., Fuso, A., Sevin, E., Businaro, R., Gosselet, F., Fénart, L., & Candela, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030934 · Cited by 66
Rapid in vivo measurement of β-amyloid reveals biphasic clearance kinetics in an Alzheimer’s mouse model
Yuede, C. M., Lee, H. J., Restivo, J. L., Davis, T. A., Hettinger, J. C., Wallace, C. E., Young, K. L., Hayne, M. R., Bu, G., Li, C.-Z., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151428 · Cited by 65
Self-citation
High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity
Qosa, H., Mohamed, L. A., Rihani, S. B. A., Batarseh, Y. S., Duong, Q.-V., Keller, J. N., & Kaddoumi, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151179 · Cited by 64
Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model
Cirrito, J. R., Wallace, C. E., Yan, P., Davis, T. A., Gardiner, W. D., Doherty, B. M., King, D., Yuede, C. M., Lee, J., & Sheline, Y. I. (2020) · Neurology · doi:10.1212/wnl.0000000000010733 · Cited by 65
Self-citation
P-Glycoprotein Function at the Blood–Brain Barrier Imaged Using 11 C- N-Desmethyl -Loperamide in Monkeys
Liow, J., Kreisl, W. C., Zoghbi, S. S., Lazarova, N., Seneca, N. M., Gladding, R. L., Taku, A. K., Herscovitch, P., Pike, V. W., & Innis, R. B. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.056226 · Cited by 63
Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model
Mohamed, L. A., Keller, J. N., & Kaddoumi, A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.01.013 · Cited by 65
Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier
Osgood, D., Miller, M. C., Messier, A. A., Gonzalez, L., & Silverberg, G. D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.011 · Cited by 63
Contribution of Gut Microbiota to Immunological Changes in Alzheimer’s Disease
van Olst, L., Roks, S. J. M., Kamermans, A., Verhaar, B. J. H., van der Geest, A. M., Muller, M., van der Flier, W. M., & de Vries, H. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683068 · Cited by 68
Recent advances in Bio-conjugated nanocarriers for crossing the Blood-Brain Barrier in (pre-)clinical studies with an emphasis on vesicles
Poustforoosh, A., Nematollahi, M. H., Hashemipour, H., & Pardakhty, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.015 · Cited by 62
Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer’s disease and strategies for treatment
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery
Cox, B., Nicolaï, J., & Williamson, B. (2022) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2331 · Cited by 73
Effects of oxysterols on the blood–brain barrier: Implications for Alzheimer’s disease
Gosselet, F., Saint-Pol, J., & Fenart, L. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.059 · Cited by 53
An investigation into the role of P-glycoprotein in Alzheimer's disease lesion pathogenesis
Jeynes, B., & Provias, J. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.10.063 · Cited by 61
Innate immune sensors and regulators at the blood brain barrier: focus on toll-like receptors and inflammasomes as mediators of neuro-immune crosstalk and inflammation
Acıoğlu, Ç., & Elkabes, S. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03360-3 · Cited by 67
Mixed oligomers and monomeric amyloid-β disrupts endothelial cells integrity and reduces monomeric amyloid-β transport across hCMEC/D3 cell line as an in vitro blood–brain barrier model
Qosa, H., LeVine, H., Keller, J. N., & Kaddoumi, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.029 · Cited by 64
Increased amyloid β-peptide (1–40) level in brain of streptozotocin-induced diabetic rats
Liu, Y., Liu, H., Yang, J., Liu, X., Lü, S., Wen, T., Xie, L. Y., & Wang, G. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.03.019 · Cited by 59
Anti-Alzheimer’s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential
Kabir, M. T., Uddin, M. S., Jeandet, P., Emran, T. B., Mitra, S., Albadrani, G. M., Sayed, A. A., Abdel‐Daim, M. M., & Simal‐Gándara, J. (2021) · Marine Drugs · doi:10.3390/md19050251 · Cited by 65
Enhanced Proteolytic Clearance of Plasma Aβ by Peripherally Administered Neprilysin Does Not Result in Reduced Levels of Brain Aβ in Mice
Walker, J. R., Pacoma, R., Watson, J., Ou, W., Alves, J., Mason, D. E., Peters, E. C., Urbina, H. D., Welzel, G., Althage, A., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3407-12.2013 · Cited by 59
Sink Hypothesis and Therapeutic Strategies for Attenuating Aβ Levels
Zhang, Y., & Lee, D. H. S. (2011) · The Neuroscientist · doi:10.1177/1073858410381532 · Cited by 61
The Role of the Blood-Brain Barrier in the Pathogenesis of Senile Plaques in Alzheimer’s Disease
Provias, J., & Jeynes, B. (2014) · International Journal of Alzheimer s Disease · doi:10.1155/2014/191863 · Cited by 60
Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats
Mohamed, L. A., Qosa, H., & Kaddoumi, A. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00040 · Cited by 58
Protective Role of St. John’s Wort and Its Components Hyperforin and Hypericin against Diabetes through Inhibition of Inflammatory Signaling: Evidence from In Vitro and In Vivo Studies
Novelli, M., Masiello, P., Beffy, P., & Menegazzi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218108 · Cited by 63
Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium
d’Uscio, L. V., He, T., & Katušić, Z. S. (2016) · Physiology · doi:10.1152/physiol.00021.2016 · Cited by 57
Abundance of P‐Glycoprotein and Other Drug Transporters at the Human Blood‐Brain Barrier in Alzheimer’s Disease: A Quantitative Targeted Proteomic Study
Storelli, F., Billington, S. F., Kumar, A. R., & Unadkat, J. D. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2035 · Cited by 60
Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier
Kuntz, M., Candela, P., Saint-Pol, J., Lamartinière, Y., Boucau, M.-C., Sevin, E., Fenart, L., & Gosselet, F. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150469 · Cited by 55
Loss of Par-1a/MARK3/C-TAK1 Kinase Leads to Reduced Adiposity, Resistance to Hepatic Steatosis, and Defective Gluconeogenesis
Lennerz, J. K., Hurov, J., White, L. S., Lewandowski, K. T., Prior, J. L., Planer, G. J., Gereau, R. W., Piwnica-Worms, D., Schmidt, R. E., & Piwnica-Worms, H. M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01472-09 · Cited by 59
Use of PET Imaging to Evaluate Transporter‐Mediated Drug‐Drug Interactions
Langer, O. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.722 · Cited by 57
Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer's disease
Chen, K.-D., Chang, P.-T., Ping, Y., Lee, H., Yeh, C., & Wang, P. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.023 · Cited by 54
Preventing P-gp Ubiquitination Lowers Aβ Brain Levels in an Alzheimer’s Disease Mouse Model
Hartz, A. M. S., Zhong, Y., Shen, A. N., Abner, E. L., & Bauer, B. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00186 · Cited by 54
Drug Permeability: From the Blood–Brain Barrier to the Peripheral Nerve Barriers
Sun, Y., Zabihi, M., Li, Q., Li, X., Kim, B. J., Ubogu, E. E., Raja, S. N., Wesselmann, U., & Zhao, C. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202200150 · Cited by 59
Association between the ABCG2 C421A polymorphism and Alzheimer's disease
Fehér, Á., Juhász, A., László, A., Pákáski, M., Kálmán, J., & Janka, Z. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.06.044 · Cited by 52
A-Subclass ATP-Binding Cassette Proteins in Brain Lipid Homeostasis and Neurodegeneration
Piehler, A. P., Özcürümez, M. K., & Kaminski, W. E. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00017 · Cited by 61
The Blood-Brain Barrier
Pan, W., & Kastin, A. J. (2016) · The Neuroscientist · doi:10.1177/1073858416639005 · Cited by 58
The A‐B‐C of small‐molecule ABC transport protein modulators: From inhibition to activation—a case study of multidrug resistance‐associated protein 1 (ABCC1)
Wiese, M., & Stefan, S. M. (2019) · Medicinal Research Reviews · doi:10.1002/med.21573 · Cited by 53
Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level
Rihani, S. B. A., Darakjian, L. I., Deodhar, M., Dow, P., Turgeon, J., & Michaud, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073742 · Cited by 55
Methodologies to Assess Drug Permeation Through the Blood–Brain Barrier for Pharmaceutical Research
Passeleu, C. L. B., Carrupt, P., Scherrmann, J. M. G., & Martel, S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1119-z · Cited by 55
Computer-Aided Drug Design Applied to Marine Drug Discovery: Meridianins as Alzheimer’s Disease Therapeutic Agents
Llorach-Parés, L., Nonell‐Canals, A., Sánchez-Martínez, M., & Àvila, C. (2017) · Marine Drugs · doi:10.3390/md15120366 · Cited by 52
The case for blood–brain barrier dysfunction in the pathogenesis of Alzheimer's disease
Jeynes, B., & Provias, J. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22527 · Cited by 51
RIFAMPICIN: An antibiotic with brain protective function
Yuluğ, B., Hanoğlu, L., Kılıç, E., & Schabitz, W. R. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2014.05.007 · Cited by 51
N-desmethyl-Loperamide Is Selective for P-Glycoprotein among Three ATP-Binding Cassette Transporters at the Blood-Brain Barrier
Kannan, P., Brimacombe, K. R., Zoghbi, S. S., Liow, J., Morse, C. L., Taku, A. K., Pike, V. W., Halldin, C., Innis, R. B., Gottesman, M. M., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031161 · Cited by 51
ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy
Carrano, A., Snkhchyan, H., Kooij, G., van der Pol, S., van Horssen, J., Veerhuis, R., Hoozemans, J., Rozemuller, A., & de Vries, H. E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.015 · Cited by 51
The impact of ATP-binding cassette transporters in the diseased brain: Context matters
Baltira, C., Aronica, E., Elmquist, W. F., Langer, O., Löscher, W., Sarkaria, J. N., Wesseling, P., de Gooijer, M. C., & van Tellingen, O. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101609 · Cited by 54
Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice
Petiet, A., Santin, M. D., Bertrand, A., Wiggins, C. J., Petit, F., Houitte, D., Hantraye, P., Bénavidès, J., Debeir, T., Rooney, T., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.009 · Cited by 54
Vascular and extravascular distribution of the ATP-binding cassette transporters ABCB1 and ABCC1 in aged human brain and pituitary
Bernstein, H., Hölzl, G., Dobrowolny, H., Hildebrandt, J., Trübner, K., Krohn, M., Bogerts, B., & Pahnke, J. (2014) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2014.08.003 · Cited by 50
Radioligands targeting P‐glycoprotein and other drug efflux proteins at the blood–brain barrier
Wanek, T., Mairinger, S., & Langer, O. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2993 · Cited by 50
The E3 Ubiquitin Ligases, HUWE1 and NEDD4-1, Are Involved in the Post-translational Regulation of the ABCG1 and ABCG4 Lipid Transporters
Aleidi, S. M., Howe, V., Sharpe, L. J., Yang, A., Rao, G., Brown, A. J., & Gelissen, I. C. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.675579 · Cited by 49
ABCA7 Downregulation Modifies Cellular Cholesterol Homeostasis and Decreases Amyloid-β Peptide Efflux in an in vitro Model of the Blood-Brain Barrier
Lamartinière, Y., Boucau, M.-C., Dehouck, L., Krohn, M., Pahnke, J., Candela, P., Gosselet, F., & Fenart, L. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170883 · Cited by 50
Changes of Blood-Brain Barrier and Brain Parenchymal Protein Expression Levels of Mice under Different Insulin-Resistance Conditions Induced by High-Fat Diet
Ogata, S., Ito, S., Masuda, T., & Ohtsuki, S. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2674-8 · Cited by 50
Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review
Wojtunik‐Kulesza, K. A., Rudkowska, M., Kasprzak‐Drozd, K., Oniszczuk, A., & Borowicz, K. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147366 · Cited by 51
Exploring the Contribution of Estrogen to Amyloid-Beta Regulation: A Novel Multifactorial Computational Modeling Approach
Anastasio, T. J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00016 · Cited by 49
P-glycoprotein transporter in drug development
Prachayasittikul, V., & Prachayasittikul, V. (2016) · EXCLI journal · doi:10.17179/excli2015-768 · Cited by 49
Vitamin D Supplementation Appears to Increase Plasma Aβ40 in Vitamin D Insufficient Older Adults: A Pilot Randomized Controlled Trial
Miller, B., Whisner, C. M., & Johnston, C. S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150901 · Cited by 48
Accumulation of murine amyloid-β mimics early Alzheimer’s disease
Krohn, M., Bracke, A., Avchalumov, Y., Schumacher, T., Hofrichter, J., Paarmann, K., Fröhlich, C., Lange, C., Brüning, T., von Bohlen und Halbach, O., et al. (2015) · Brain · doi:10.1093/brain/awv137 · Cited by 47
Vascular Neural Network Phenotypic Transformation After Traumatic Injury: Potential Role in Long-Term Sequelae
Badaut, J., & Bix, G. J. (2013) · Translational Stroke Research · doi:10.1007/s12975-013-0304-z · Cited by 48
Cognitive benefits of lithium chloride in APP/PS1 mice are associated with enhanced brain clearance of β-amyloid
Pan, Y., Short, J. L., Newman, S. A., Choy, K. H. C., Tiwari, D., Yap, C., Senyschyn, D., Banks, W. A., & Nicolazzo, J. A. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.03.007 · Cited by 50
Immunohistochemical analysis of transporters related to clearance of amyloid-β peptides through blood–cerebrospinal fluid barrier in human brain
Matsumoto, K., Chiba, Y., Fujihara, R., Kubo, H., Sakamoto, H., & Ueno, M. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1366-7 · Cited by 46
Glycoproteomics Landscape of Asymptomatic and Symptomatic Human Alzheimer’s Disease Brain
Suttapitugsakul, S., Stavenhagen, K., Donskaya, S., Bennett, D. A., Mealer, R. G., Seyfried, N. T., & Cummings, R. D. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100433 · Cited by 48
Evaluation of hypoxia inducible factor expression in inflammatory and neurodegenerative brain models
de Lemos, M. L., de la Torre, A. V., Petrov, D., Brox, S., Folch, J., Pallàs, M., Lazarowski, A., Beas‐Zárate, C., Auladell, C., & Camins, A. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.04.011 · Cited by 47
Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease
Martiskainen, H., Haapasalo, A., Kurkinen, K. M. A., Pihlajamäki, J., Soininen, H. S., & Hiltunen, M. O. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.789862 · Cited by 49
Role of Vitamin D in Amyloid clearance via LRP-1 upregulation in Alzheimer’s disease: A potential therapeutic target?
Patel, P., & Shah, J. (2017) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.06.007 · Cited by 46
Alteration in the Function and Expression of SLC and ABC Transporters in the Neurovascular Unit in Alzheimer’s Disease and the Clinical Significance
Jia, Y., Wang, N., Zhang, Y., Xue, D., Lou, H., & Liu, X. (2020) · Aging and Disease · doi:10.14336/ad.2019.0519 · Cited by 50
Drug Access to the Central Nervous System in Alzheimer’s Disease: Preclinical and Clinical Insights
Mehta, D. C., Short, J. L., Hilmer, S. N., & Nicolazzo, J. A. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1522-0 · Cited by 47
Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Ueno, M. (2009) · Current Neuropharmacology · doi:10.2174/157015909788848901 · Cited by 44
Clinico-Pathologic Function of Cerebral ABC Transporters – Implications for the Pathogenesis of Alzheimers Disease
Pahnke, J., Wolkenhauer, O., Krohn, M., & Walker, L. C. (2008) · Current Alzheimer Research · doi:10.2174/156720508785132262 · Cited by 45
Mint Proteins Are Required for Synaptic Activity-dependent Amyloid Precursor Protein (APP) Trafficking and Amyloid β Generation
Sullivan, S. E., Dillon, G. M., Sullivan, J. M., & Ho, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.541003 · Cited by 44
The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Cataldi, M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030004 · Cited by 45
Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies
Ballatore, C., Brunden, K. R., Trojanowski, J. Q., Lee, V. M. Y., Smith, A. B., & Huryn, D. M. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611794072605 · Cited by 46
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study
Liu, L., Collier, A. C., Link, J. M., Domino, K. B., Mankoff, D. A., Eary, J. F., Spiekerman, C. F., Hsiao, P., Deo, A. K., & Unadkat, J. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058685 · Cited by 45
Microphysiological systems for recapitulating physiology and function of blood-brain barrier
Seo, S., Kim, H., Sung, J. H., Choi, N., Lee, K., & Kim, H. N. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119732 · Cited by 46
Transport of Alzheimer’s associated amyloid-β catalyzed by P-glycoprotein
McCormick, J. W., McCormick, L. A., (党陈), G. C., Vogel, P. D., & Wise, J. G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250371 · Cited by 43
Increased Type I interferon signaling and brain endothelial barrier dysfunction in an experimental model of Alzheimer’s disease
Jana, A., Wang, X., Leasure, J. W., Magana, L., Wang, L., Kim, Y.-M., Dodiya, H., Toth, P. T., Sisodia, S. S., & Rehman, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-20889-y · Cited by 43
Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt–Jakob disease
Vogelgesang, S., Glatzel, M., Walker, L. C., Kroemer, H. K., Aguzzi, A., & Warzok, R. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0042-3 · Cited by 43
Evaluation of [ 18 F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood–brain barrier in rats: Kinetics, metabolism, and selectivity
Savolainen, H., Windhorst, A. D., Elsinga, P. H., Cantore, M., Colabufo, N. A., Willemsen, A. T. M., & Luurtsema, G. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16654493 · Cited by 43
Linking activity dyshomeostasis and sleep disturbances in Alzheimer disease
Slutsky, I. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00797-y · Cited by 43

Authors: Cirrito, J. R.
Affiliations: Washington University in St. Louis (US)
Corresponding author: Cirrito, J. R.
ORCID: Cirrito, J. R.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2005-11-01
Volume: 115
Issue: 11
Pages: 3285-3290
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci25247
PMC: PMC1257538
OpenAlex: W2163209521
Cited by: 660
References: 34
Citations by year: 2026: 21 · 2025: 24 · 2024: 29 · 2023: 36 · 2022: 31 · 2021: 30 · 2020: 37 · 2019: 31 · 2018: 30 · 2017: 35 · 2016: 43 · 2015: 40 · 2014: 41 · 2013: 44 · 2012: 26
FWCI: 12.44
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
Funders: U.S. Department of Energy
National Institutes of Health (CA94056, AG13956)
National Institute on Aging (AG023316, R03AG023316, R01AG023084, AG23084, R01AG013956, R37AG023084, R37AG013956)
National Cancer Institute (P50 CA94056, P50CA094056)
National Institute of Allergy and Infectious Diseases (AI-13956)
National Institute of Neurological Disorders and Stroke (NS034467, R37NS034467, R01NS034467)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords: P-glycoprotein, blood-brain barrier, amyloid-beta, Alzheimer's disease, APP transgenic mice, P-glycoprotein inhibitors, brain interstitial fluid, amyloid-beta clearance, brain microvascular endothelial cells, amyloid-beta deposition
MeSH terms: Alzheimer Disease, Animals, Blood-Brain Barrier, Disease Models, Animal, Mice, Inbred C57BL, Mice, Transgenic, Polymorphism, Genetic, Up-Regulation, Amyloid beta-Peptides, Mice, Knockout, ATP Binding Cassette Transporter, Subfamily B, Member 1, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

P-glycoprotein deficiency at the blood-brain barrier increases amyloid- deposition in an Alzheimer disease mouse model

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks